Direct Oral Anticoagulants and Bleeding Risk (in Comparison to Vitamin K Antagonists and Heparins), and the Treatment of Bleeding

Seminars in Hematology

Volumn 51, Issue 2, 2014, Pages 102-111

  Palareti, Gualtiero ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; EDOXABAN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHRONIC DRUG ADMINISTRATION; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HEPARIN; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84901364162     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.02.002     Document Type: Article

References (71)

1. Wysowski D.K., Nourjah P., Swartz L. Bleeding complications with warfarin use-a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
2. Hylek E.M., Dantonio J., EvansMolina C., Shea C., Henault L.E., Regan S. Translating the results of randomized trials into clinical practice-the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006, 37:1075-1078.
3. Gussoni G., Di Pasquale G., Vescovo G., et al. Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study. Eur J Intern Med 2013, 24:324-332.
4. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782.
5. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes-an analysis from the ACUITY trial. J Am Coll Cardiol 2007, 49:1362-1368.
6. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
7. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
8. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
9. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
10. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
11. Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3:692-694.
12. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
13. Ezekowitz M.D., Wallentin L., Connolly S.J., et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010, 122:2246-2253.
14. Oldgren J., Alings M., Darius H., et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011, 155:660-667. W204.
15. Wallentin L., Yusuf S., Ezekowitz M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
16. Wallentin L., Lopes R.D., Hanna M., et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013, 127:2166-2176.
17. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138. 1093-10.
18. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011, 58:395-401.
19. Johnston J.A., Cluxton R.J., Heaton P.C., Guo J.J., Moomaw C.J., Eckman M.H. Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 2003, 163. 1705-1.
20. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
21. Legrand M., Mateo J., Aribaud A., et al. The use of dabigatran in elderly patients. Arch Intern Med 2011, 171:1285-1286.
22. Lillo-Le Louet A., Wolf M., Soufir L., et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012, 108:583-585.
23. Cano E.L., Miyares M.A. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012, 10:160-163.
24. Garber S.T., Sivakumar W., Schmidt R.H. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012, 116:1093-1096.
25. Bene J., Said W., Rannou M., Deheul S., Coupe P., Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012, 46:e14.
26. Wychowski M.K., Kouides P.A. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012, 46:e1.
27. Yokoi K., Isoda K., Kimura T., Adachi T. Diffuse alveolar hemorrhage associated with dabigatran. Intern Med 2012, 51:2667-2668.
28. Southworth M.R., Reichman M.E., Unger E.F. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013, 368:1272-1274.
29. US Food and Drug Adminstration. http://mini-sentinel.org.
30. Larsen T.B., Rasmussen L.H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61:2264-2273.
31. Sorensen R., Gislason G., Torp-Pedersen C., et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013, 3:e002758.
32. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
33. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369:1406-1415.
34. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363. 2499-51.
35. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
36. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:799-808.
37. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
38. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368:699-708.
39. Adam S.S., McDuffie J.R., Ortel T.L., Williams J.W. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012, 157:796-807.
40. Dentali F., Riva N., Crowther M., Turpie A.G., Lip G.Y., Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012, 126:2381-2391.
41. Miller C.S., Grandi S.M., Shimony A., Filion K.B., Eisenberg M.J. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110:453-456.
42. Liu T., Korantzopoulos P., Li L., Li G. Survival benefit of new anticoagulants compared with warfarin in patients with atrial fibrillation: a meta-analysis. Int J Cardiol 2012, 156:96-97.
43. Fox B.D., Kahn S.R., Langleben D., Eisenberg M.J., Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012, 345:e7498.
44. Desai J., Kolb J.M., Weitz J.I., Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies. Thromb Haemost 2013, 110:205-212.
45. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011, 9:1705-1712.
46. Pengo V., Crippa L., Falanga A., et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011, 106:868-876.
47. Miesbach W., Seifried E. New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012, 108:625-632.
48. Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013, 34:2094-2106.
49. Pernod G., Albaladejo P., Godier A., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March. 2013. Arch Cardiovasc Dis 2013, 106:382-393.
50. Palareti G., Ageno W., Ferrari A., et al. Clinical management of rivaroxaban-treated patients. Expert Opin Pharmacother 2013, 14:655-667.
51. Lu G., DeGuzman F.R., Hollenbach S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19:446-451.
52. Schiele F., van Ryn J., Canada K., et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013, 121:3554-3562.
53. Favaloro E.J., Lippi G., Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology (Phila) 2011, 43:682-692.
54. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013, 121:4032-4035.
55. Tsakiris D.A. Direct oral anticoagulants: interference with laboratory tests and mechanisms of action. Semin Hematol 2014, 51. xx-xx.
56. Landefeld C.S., Rosenblatt M.W., Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989, 87:153-159.
57. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
58. Chang D.N., Dager W.E., Chin A.I. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013, 61:487-489.
59. Warkentin T.E., Margetts P., Connolly S.J., Lamy A., Ricci C., Eikelboom J.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012, 119:2172-2174.
60. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013, 109:596-605.
61. Godier A., Miclot A., Le Bonniec B., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116:94-102.
62. Fukuda T., Honda Y., Kamisato C., Morishima Y., Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012, 107:253-259.
63. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599.
64. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
65. Key N.S., Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007, 370:439-448.
66. Marlu R., Hodaj E., Paris A., Albaladejo P., Crackowski J.L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
67. Khoo T.L., Weatherburn C., Kershaw G., Reddel C.J., Curnow J., Dunkley S. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013, 35:222-224.
68. Levi M., Levy J.H., Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363. 1791-80.
69. Shakur H., Roberts R., Bautista R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376:23-32.
70. Poli D., Antonucci E., Grifoni E., Abbate R., Gensini G.F., Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009, 101:367-372.
71. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010, 363:1875-1876.